Considering the difference between these mice and individuals with AD in sleep/wake structure, further studies are required to evaluate if OX2R agonists can decrease tau accumulation in individuals with AD with hypersomnia by promoting neural activity-dependent efflux of tau from neurons. The gene discussed is MAPT; the disease is Alzheimer disease.